Ebru Damadoğlu

555 total citations
53 papers, 267 citations indexed

About

Ebru Damadoğlu is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pharmacology. According to data from OpenAlex, Ebru Damadoğlu has authored 53 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 17 papers in Physiology and 12 papers in Pharmacology. Recurrent topics in Ebru Damadoğlu's work include Asthma and respiratory diseases (16 papers), Drug-Induced Adverse Reactions (11 papers) and Urticaria and Related Conditions (9 papers). Ebru Damadoğlu is often cited by papers focused on Asthma and respiratory diseases (16 papers), Drug-Induced Adverse Reactions (11 papers) and Urticaria and Related Conditions (9 papers). Ebru Damadoğlu collaborates with scholars based in Türkiye, Kuwait and Ireland. Ebru Damadoğlu's co-authors include Alı Fuat Kalyoncu, Gül Karakaya, Polat Göktaş, Adnan Yılmaz, Sinem Güngör, Esen Akkaya, Adnan Yılmaz, Cüneyt Saltürk, Huriye Berk Takır and Erdal Okur and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nutrients and Clinical & Experimental Allergy.

In The Last Decade

Ebru Damadoğlu

39 papers receiving 249 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ebru Damadoğlu Türkiye 8 69 61 57 43 34 53 267
Veronica Rizzo Italy 11 82 1.2× 22 0.4× 122 2.1× 59 1.4× 4 0.1× 28 314
Andrew McDonald South Africa 11 50 0.7× 13 0.2× 18 0.3× 14 0.3× 25 0.7× 36 280
Ramez Philips United States 10 60 0.9× 116 1.9× 17 0.3× 26 0.6× 19 0.6× 39 314
Ja Youn Lee South Korea 10 70 1.0× 207 3.4× 113 2.0× 19 0.4× 19 0.6× 13 454
Melissa H. Coleman United States 9 98 1.4× 63 1.0× 38 0.7× 5 0.1× 3 0.1× 13 314
Aaron J. Feinstein United States 11 95 1.4× 152 2.5× 16 0.3× 39 0.9× 16 0.5× 18 339
Elisabeth Mlczoch Austria 9 63 0.9× 65 1.1× 30 0.5× 39 0.9× 4 0.1× 20 297
Nikolas Ruffer Germany 11 60 0.9× 36 0.6× 25 0.4× 14 0.3× 36 330
Lindsey Mitrani United States 8 52 0.8× 47 0.8× 63 1.1× 12 0.3× 20 322
Nicholas L.J. Chornenki Canada 9 29 0.4× 47 0.8× 10 0.2× 23 0.5× 6 0.2× 23 348

Countries citing papers authored by Ebru Damadoğlu

Since Specialization
Citations

This map shows the geographic impact of Ebru Damadoğlu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ebru Damadoğlu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ebru Damadoğlu more than expected).

Fields of papers citing papers by Ebru Damadoğlu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ebru Damadoğlu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ebru Damadoğlu. The network helps show where Ebru Damadoğlu may publish in the future.

Co-authorship network of co-authors of Ebru Damadoğlu

This figure shows the co-authorship network connecting the top 25 collaborators of Ebru Damadoğlu. A scholar is included among the top collaborators of Ebru Damadoğlu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ebru Damadoğlu. Ebru Damadoğlu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Damadoğlu, Ebru, et al.. (2025). Comparison of the characteristics of patients with chronic urticaria receiving standard- or high-dose omalizumab. European Annals of Allergy and Clinical Immunology. 58(2). 69–69. 1 indexed citations
2.
3.
Damadoğlu, Ebru, et al.. (2025). Clinical characteristics and biological treatment responses of patients with late-onset asthma phenotype. Allergy and Asthma Proceedings. 46(2). 109–118.
4.
Damadoğlu, Ebru, et al.. (2024). Successful desensitization in a patient with metastatic colorectal cancer presenting with regorafenib-mediated fix drug eruption. Cancer Chemotherapy and Pharmacology. 94(6). 815–818.
5.
Damadoğlu, Ebru, et al.. (2024). The association between baseline IgE level and urticaria control at six months of omalizumab treatment in chronic urticaria. European Annals of Allergy and Clinical Immunology. 1 indexed citations
6.
Yalçın, Nadir, et al.. (2024). Effect of Modulator Therapies on Nutritional Risk Index in Adults with Cystic Fibrosis: A Prospective Cohort Study. Nutrients. 16(12). 1811–1811. 1 indexed citations
7.
Damadoğlu, Ebru, et al.. (2023). Cytokine Profiles of Chronic Urticaria Patients and the Effects of Omalizumab Treatment. Dermatology Practical & Conceptual. 13(4). e2023272–e2023272. 4 indexed citations
8.
Damadoğlu, Ebru, et al.. (2023). Comparison of the clinical outcomes of patients with NSAID-exacerbated respiratory disease receiving aspirin or biologicals. Journal of Asthma. 60(10). 1885–1894. 2 indexed citations
9.
Çelík, Gülfem, Gül Karakaya, Ferda Öner Erkekol, et al.. (2023). Comparison of 300 mg versus 600 mg daily maintenance doses of aspirin treatment after desensitization in N-ERD: A three-year multicentre experience. Allergy and Asthma Proceedings. 44(2). 106–114.
10.
Göktaş, Polat, Gül Karakaya, Alı Fuat Kalyoncu, & Ebru Damadoğlu. (2023). Artificial Intelligence Chatbots in Allergy and Immunology Practice: Where Have We Been and Where Are We Going?. The Journal of Allergy and Clinical Immunology In Practice. 11(9). 2697–2700. 38 indexed citations
11.
Göktaş, Polat, et al.. (2023). Thermo‐SPT: A new skin prick test evaluation framework based on low‐cost, portable smartphone thermography. Clinical & Experimental Allergy. 53(6). 626–635. 3 indexed citations
12.
13.
14.
15.
Damadoğlu, Ebru, et al.. (2022). SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis. Annals of Allergy Asthma & Immunology. 128(6). 733–734. 4 indexed citations
16.
Bılgın, Emre, Ertuğrul Çağrı Bölek, Serdar Özer, et al.. (2021). The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?. Internal and Emergency Medicine. 17(3). 743–751. 7 indexed citations
17.
Damadoğlu, Ebru, et al.. (2020). A practical method of drug provocation testing to prove tolerance to alternative drugs in drug hypersensitivity. TURKISH JOURNAL OF MEDICAL SCIENCES. 51(2). 604–609. 1 indexed citations
18.
19.
Damadoğlu, Ebru. (2020). Adult Primary Antibody Deficiencies and the Lung. Turkish Thoracic Journal.
20.
Yılmaz, Adnan, et al.. (2008). Delays in the Diagnosis and Treatment of Primary Lung Cancer: Are Longer Delays Associated with Advanced Pathological Stage?. Upsala Journal of Medical Sciences. 113(3). 287–296. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Veronica Rizzo Breakdown of academic impact, for papers by Andrew McDonald Breakdown of academic impact, for papers by Ramez Philips Breakdown of academic impact, for papers by Ja Youn Lee Breakdown of academic impact, for papers by Melissa H. Coleman Breakdown of academic impact, for papers by Aaron J. Feinstein Breakdown of academic impact, for papers by Elisabeth Mlczoch Breakdown of academic impact, for papers by Nikolas Ruffer Breakdown of academic impact, for papers by Lindsey Mitrani Breakdown of academic impact, for papers by Nicholas L.J. Chornenki
Rankless by CCL
2026